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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A34Methods: Primary human chondrocytes from human donors (mean ±
SD 76,75 ± 3,30 years, n¼3) were transfected with siRNA for Atg5 (100
nM, 72 hours), an important autophagy marker, and silencer negative
control siRNA (100 nM) used as control to block the autophagy pathway.
To identify the key proteins responding to defective autophagy, we
performed a quantitative proteomics analysis of autophagy-deﬁcient
human chondrocytes using labeling iTRAQ (isobaric tags for relative and
absolute quantitation) coupled with on-line 2D LC/MS/MS. Protein
identiﬁcation and quantiﬁcation were performed using Protein Pilot
Software v 4.0 (ABSciex). Each MS/MS spectrum was searched in the
Uniprot/Swissprot database for Homo sapiens. The String database was
employed to ﬁnd putative protein-protein interactions. To validate the
candidate targets identiﬁed by the proteomic screening, inmortalized
human chondrocytes (Tc28a2), Human cartilage from healthy, aged and
osteoarthritis human patients and mouse knee joints from young and
old mice were employed to perform Western Blot (WB), Inmuno-
ﬂuorescence (IF) and Inmunohistochemistry (IHC) analysis, respec-
tively. The candidate targets were: Atg5 and LC3 for constitutive
autophagy, p62, as a defective autophagy marker, Lamin A/C as an aging
marker and Filamin A, as a cytoskeleton marker.
Results: From the total of 1216 proteins found, 21 were signiﬁcantly
altered (p < 0.05) in at least two donors from a total number of three.
However, only prelamin A/C, a nuclear protein implicated in premature
cell senescence, was signiﬁcantly upregulated in all the donors (p <
0.05). Furthermore, proteins involved in the cytoskeleton organization,
collagen catabolism, oxidative stress, and aging were identiﬁed in
deﬁcient autophagy chondrocytes. Interestingly, the String Database
Software indicates a direct interaction between Filamin A, a cytoske-
leton protein (p < 0.05) and Prelamin A/C, an aging marker, that were
downregulated and upregulated ,respectively when autophagy is
blocked. To conﬁrm this association, TC28a2 human chondrocytes were
transfected with siAtg5 and silencer negative control siRNA. Then, the
expression of autophagy proteins, such as Atg5 and LC3, the levels of
p62, Lamin A/C and Filamin A was evaluated. The results indicated a
reduction in autophagy expression, accompanied with an increase in
p62 and Lamin A/C and a reduction in Filamin A expression. Impor-
tantly, in human cartilage from both aged and OA patients, autophagy
markers were signiﬁcantly downregulated and Lamin A/C expression
was upregulated, compared to healthy cartilage. To stablish the validity
of these results, articular cartilage from a spontaneous aging mice
model was studied. Histology analysis of mouse knee joints from young
mice (4 months old mice) and old mice (28 months old) revealed a
reduction in Atg5 and LC3 expression, as well as an increase in Lamin A/
C expression, suggesting that autophagy loss-of-function is directly
correlated with premature senescence in articular cartilage.
Conclusions: Proteomics analysis of joint cells and tissue has revealed
features of premature senescence when autophagy is disrupted in
chondrocytes and cartilage. Lamin, nuclear protein contributing to
structural integrity to the nucleus and matrix was identiﬁed as candi-
date targets for regulating cartilage function in situations of defective
autophagy, including aging and OA. These results support the hypoth-
esis that autophagy is decreased with aging, affect nuclear and matrix
structural integrity, and represents a key mechanism in the develop-
ment of cartilage degradation. Therefore, targeting lamin is a promising
strategy to ﬁnd novel therapeutics for cartilage aging and OA.
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EVALUATION OF THE BENEFIT OF CORTICOSTEROID INJECTION
PRIOR TO EXERCISE THERAPY IN PATIENTS WITH KNEE
OSTEOARTHRITIS: A RANDOMIZED TRIAL
M. Henriksen, R. Christensen, L. Klokker, C. Bartholdy, K. Ellegaard,
M. Boesen, R. Riis, E. Bartels, H. Bliddal. The Parker Inst., Copenhagen,
Denmark
Purpose: Combined non-pharmacological and pharmacological treat-
ment is recommended as optimal management of knee osteoarthritis
(OA). However, the two treatment approaches have mostly been
investigated separately. We aimed to assess the efﬁcacy of combined
intra-articular corticosteroid injection and exercise compared to pla-
cebo injection and exercise in patients with knee OA.
Methods: This randomized, double blind, placebo-controlled trial
running over 26 weeks was designed as a superiority study comparing
the efﬁcacy of a single intra-articular corticosteroid injection (1 mL of
40 mg/mL methylprednisolone dissolved in 4 mL 10 mg/mL Lidocaine)
plus exercise, with a single placebo injection (1 mL isotonic salinemixed with 4 mL 10 mg/mL Lidocaine) plus exercise. Participants with
clinical and radiographic knee OA were randomly allocated (1:1) to
either corticosteroid (Steroid Group) or saline (Placebo Group) injec-
tion. Two weeks after injection, all participants started a 12 week
supervised exercise program with 3 weekly sessions. Outcomes were
assessed at baseline, week 2 (exercise start), week 14 (end of exercise),
and week 26 (follow-up). The primary outcomewas themean change in
KOOS pain subscale at week 14. Analyses were done on the intention-
to-treat (ITT) population (all randomized participants). Missing data
were replaced using multiple imputation. A repeated measures mixed
model was used to analyze the primary outcome; week, treatment, and
week x treatment were included as ﬁxed effects, adjusting for the
baseline value.
Results: A total of 263 patients were screened and 100 patients were
randomized to receive either Steroid (n¼50) or Placebo (n¼50). Of
these, 93 completed the week 14 assessment and 89 completed the 26
weeks trial. There were no group differences in the proportions com-
pleting. Mean age was 63.4 (SD 9.3) years, 61% were women. The mean
exercise attendance ratewas 79% (SD 15); no group difference observed.
The mean (SD) KOOS pain score at randomization was 53.3 (11.4) and
55.2 (16.0) in the Steroid and Placebo groups, respectively. The mean
(SE) change in pain at week 14was 13.6 (1.8) and 14.8 (1.8) in the Steroid
and Placebo Groups, respectively, corresponding to amean difference of
1.2 units (95% CI -3.8 to 6.2; P¼0.64). These results were robust
according to all sensitivity analyses - incl. using baseline observation
carried-forward imputation and no imputation. There were no group
differences at week 2, 14, and 26 in any of the 5 KOOS subscales and the
95% conﬁdence intervals of the group differences did not exceed the
suggested minimal clinical important difference of 8-10 KOOS points.
Conclusions: These results show comparable efﬁcacy of intra-articular
corticosteroid and placebo when combined with exercise for pain relief
in knee OA.
Trial registration. EU clinical trials register (EudraCT): 2012-002607-18
and clinicaltrials.gov NCT01945749
17
THE COMBINED EFFICACY OF MULTIMODAL NON-SURGICAL
TREATMENT ON PAIN AND SENSITIZATION IN PATIENTS WITH
KNEE OSTEOARTHRITIS NOT ELIGIBLE FOR A TOTAL KNEE
ARTHROPLASTY e AN ANCILLARY ANALYSIS FROM A RANDOMIZED
CONTROLLED TRIAL
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Purpose: To report the efﬁcacy of a 12-week treatment program con-
sisting of neuromuscular exercise, education, diet, insoles and pain
medication (the MEDIC-treatment) compared to two leaﬂets with
information and treatment advice (usual care) in reducing pain-related
measures and sensitization in patients with knee osteoarthritis (OA) not
eligible for total knee arthroplasty (TKA).
Methods: This was a pre-deﬁned ancillary analysis of the 12-week
results from a randomized controlled trial with 100 patients random-
ized to MEDIC-treatment or usual care (Trial registration: clinicaltrials.
gov NCT01535001). The primary outcomewas peak pain intensity in the
previous 24h (VAS 0-100). Secondary outcomes included peripheral
and central sensitization assessed at the knee, the lower leg and fore-
arm (pressure pain thresholds from handheld algometry), pain inten-
sity after 30 min of walking (VAS 0-100), pain location and pattern
(Knee Pain Map), spreading of pain (a region-divided body chart) and
the usage of pain medication (pain medication during the last week due
to knee yes/no).
Results: 654 patients seen by an orthopaedic surgeon in secondary
care were assessed for eligibility, 553 were excluded and one was
not willing to undergo randomization (Primary reasons for exclu-
sion: being eligible for TKA (n¼192), not radiographic OA (Kellgren-
Lawrence score<1; n¼87), and inability to comply with study pro-
tocol (n¼159)). 100 patients were randomized with 43/50 (86%) in
the MEDIC group and 46/50 (92%) in the usual care group com-
pleting both baseline and the 12-week follow-up (see table 1 for
baseline characteristics).
The MEDIC group had a mean improvement (95% CI) in peak pain
intensity from baseline to 12 weeks that was 15.4 (2.6 to 28.2) larger
(Figure 1; P ¼ 0.019) than the usual care group. Furthermore, the
